What topical treatments are recommended for an adult with plaque psoriasis?

Topical Treatment for Plaque Psoriasis in Adults

For adults with plaque psoriasis, start with a fixed combination of calcipotriene/betamethasone dipropionate applied once daily for 4-8 weeks as initial therapy, followed by twice-weekly proactive maintenance to prevent relapse. 1

Initial Treatment Strategy

First-Line Therapy for Body Psoriasis

The combination product of calcipotriene 0.005% and betamethasone dipropionate 0.064% is the preferred initial treatment for plaque psoriasis not involving intertriginous areas 1. This recommendation is based on:

• Superior efficacy: 48% of patients achieved absent or mild disease at 4 weeks versus 16.5% with calcipotriene alone and 26.3% with betamethasone alone 2
• Long-term safety: In 52-week studies, 69-74% of patients achieved clear or almost clear status with no serious adverse events including striae or HPA axis suppression 1
• Strength of recommendation: A, Level of evidence: I 1

The aerosol foam formulation is the most effective delivery system, though formulation choice should consider patient preference and lesion location 3.

Monotherapy Options When Combination Not Available

If using topical corticosteroids alone:

• Moderate to high potency (Class 2-5) for initial therapy on most body areas 1
• Ultra-high potency (Class 1) for thick, chronic plaques - efficacy rates 58-92% at 2 weeks 1
• Duration: Up to 4 weeks initially (Strength A, Level I) 1
• Extended use: Beyond 12 weeks only under careful physician supervision (Strength C, Level III) 1

Critical caveat: Avoid abrupt discontinuation of potent corticosteroids to prevent rebound. Taper gradually by reducing frequency after clinical improvement 1.

Site-Specific Recommendations

Scalp Psoriasis

• First choice: Calcipotriene/betamethasone gel or foam for 4-12 weeks (Strength A) 1
• Alternative: Any class (1-7) topical corticosteroid for minimum 4 weeks (Strength A, Level I) 1
• Calcipotriene foam alone shows efficacy at 8 weeks (40.9% clear/almost clear) but not at 4 weeks - set patient expectations accordingly 1

Face and Intertriginous Areas

Use low-potency corticosteroids or non-steroidal alternatives due to high risk of atrophy, striae, and telangiectasia 1

Preferred non-steroidal options:

• Tacrolimus 0.1% ointment (off-label): 65% clear/almost clear at 8 weeks for facial/intertriginous psoriasis (Strength B, Level I) 1, 2
• Pimecrolimus 1% cream (off-label): 71% clear/almost clear at 8 weeks for intertriginous psoriasis (Strength B, Level I) 1, 2
• Calcipotriene with hydrocortisone or tacalcitol for facial psoriasis (Strength B) 1

Important warning: Both calcineurin inhibitors carry FDA black box warnings regarding theoretical malignancy risk, though clinical evidence to date shows no causal link 1, 2. Common side effect is burning/itching that typically improves with continued use - advise patients not to apply immediately after bathing to minimize irritation 2.

Thick, Hyperkeratotic Plaques

For limited, resistant plaques:

• Intralesional triamcinolone acetonide up to 20 mg/mL every 3-4 weeks 1
• Combination tacrolimus 0.1% with 6% salicylic acid for 12 weeks (off-label, Strength B, Level II) 1

Maintenance Strategy

After achieving initial clearance, switch to proactive maintenance with calcipotriene/betamethasone twice weekly to reduce relapse risk 3. This approach is supported by 52-week safety data showing sustained efficacy without cumulative toxicity 1.

Alternative Maintenance Regimens

• Vitamin D analogues twice daily on weekdays + high-potency corticosteroid twice daily on weekends (Strength B) 1
• Morning high-potency corticosteroid + evening vitamin D analogue (Strength B) 1

Additional Topical Agents

Vitamin D Analogues (Monotherapy)

Long-term use up to 52 weeks is safe and effective (Strength A, Level I) 1:

• Calcipotriene: 70% showed ≥75% improvement versus 19% with vehicle 2
• Apply after phototherapy if combining treatments (UVA inactivates calcipotriene; thick layers block UVB) 1
• Avoid concurrent salicylic acid - acidic pH inactivates calcipotriene 1

Tazarotene

• Efficacy: 50-63% achieve ≥50% improvement at 12 weeks (Strength A, Level I) 2
• Best used in combination with corticosteroids to reduce irritation 2
• Pregnancy Category X - absolutely contraindicated 2
• Photosensitizing - use caution with phototherapy, though combination can reduce UV exposure needed 2

Newer Non-Steroidal Option

Tapinarof 1% cream (FDA-approved 2022): Once-daily aryl hydrocarbon receptor agonist with favorable safety profile and mean 4-month disease clearance after treatment cessation 4. Consider when seeking steroid-sparing alternatives.

Common Pitfalls to Avoid

1. Using potent corticosteroids on face/intertriginous areas - high atrophy risk 1
2. Applying calcipotriene before phototherapy - reduces efficacy of both treatments 1
3. Combining calcipotriene with salicylic acid - inactivates vitamin D analogue 1
4. Abrupt corticosteroid discontinuation - causes rebound flares 1
5. Expecting rapid results from vitamin D analogues - efficacy evident at 8 weeks, not 4 weeks 1
6. Inadequate assessment for atrophy - examine forearms, face, and intertriginous areas at each visit 1

When to Escalate Beyond Topicals

If topical therapy alone is insufficient after appropriate trial (typically 8-12 weeks), escalate to phototherapy or systemic agents according to disease severity and body surface area involvement 3. Topicals remain important adjunctive therapy even when systemic treatment is initiated 1.